Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30

$1.65+0.03 (+2.17%)

Close on Nov 13, 2026Market cap $319.98MP/E –Yield –

Altimmune total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Altimmune's total debt was $34.99M at Sep 30, 2026. For fiscal 2025 it was $34.29M, up 648.5% from the year before. The highest annual figure on record is $34.29M in fiscal 2025.

Annual total debt

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$34.29M	+648.5%
FY2022	Dec 31, 2022	$4.58M	+215.1%
FY2021	Dec 31, 2021	$1.45M	-20.5%
FY2020	Dec 31, 2020	$1.83M	-2.0%
FY2019	Dec 31, 2019	$1.86M	+0.7%
FY2018	Dec 31, 2018	$1.85M	–
FY2015	Dec 31, 2015	$0	-100.0%
FY2014	Dec 31, 2014	$746.15K	-73.6%
FY2013	Dec 31, 2013	$2.82M	-25.4%
FY2012	Dec 31, 2012	$3.78M	–

Quarterly total debt

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$34.99M	+142.2%
Q2 FY2026	Jun 30, 2026	$34.74M	+142.4%
Q1 FY2026	Mar 31, 2026	$34.51M	+701.5%
Q4 FY2025	Dec 31, 2025	$34.29M	+723.2%
Q3 FY2025	Sep 30, 2025	$14.45M	+228.3%
Q2 FY2025	Jun 30, 2025	$14.33M	+212.9%
Q3 FY2023	Sep 30, 2023	$4.31M	-4.5%
Q2 FY2023	Jun 30, 2023	$4.17M	+172.9%
Q1 FY2023	Mar 31, 2023	$4.40M	+163.8%
Q4 FY2022	Dec 31, 2022	$4.58M	+215.1%
Q3 FY2022	Sep 30, 2022	$4.51M	+187.8%
Q2 FY2022	Jun 30, 2022	$1.53M	-5.6%
Q1 FY2022	Mar 31, 2022	$1.67M	-3.0%
Q4 FY2021	Dec 31, 2021	$1.45M	-20.5%
Q3 FY2021	Sep 30, 2021	$1.57M	-18.7%
Q2 FY2021	Jun 30, 2021	$1.62M	-5.7%
Q1 FY2021	Mar 31, 2021	$1.72M	-4.0%
Q4 FY2020	Dec 31, 2020	$1.83M	-2.0%
Q3 FY2020	Sep 30, 2020	$1.93M	+7.8%
Q2 FY2020	Jun 30, 2020	$1.72M	-22.5%
Q1 FY2020	Mar 31, 2020	$1.79M	-22.7%
Q4 FY2019	Dec 31, 2019	$1.86M	+0.7%
Q3 FY2019	Sep 30, 2019	$1.79M	–
Q2 FY2019	Jun 30, 2019	$2.21M	–
Q1 FY2019	Mar 31, 2019	$2.32M	–
Q4 FY2018	Dec 31, 2018	$1.85M	–